Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations.
- DOI
- 10.1016/j.jtocrr.2020.100105
- Published
- 2021 Mar
- Container
- JTO clinical and research reports
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.jtocrr.2020.100105,
title = {Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations.},
author = {Vasconcelos PENS and Kobayashi IS and Kobayashi SS and Costa DB},
year = {2021},
journal = {JTO clinical and research reports},
doi = {10.1016/j.jtocrr.2020.100105},
url = {https://doi.org/10.1016/j.jtocrr.2020.100105}
}RIS
TY - JOUR TI - Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations. AU - Vasconcelos PENS AU - Kobayashi IS AU - Kobayashi SS AU - Costa DB PY - 2021 JO - JTO clinical and research reports DO - 10.1016/j.jtocrr.2020.100105 UR - https://doi.org/10.1016/j.jtocrr.2020.100105 ER -
APA
PENS, V., IS, K., SS, K., & DB, C. (2021). Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations.. JTO clinical and research reports. https://doi.org/10.1016/j.jtocrr.2020.100105
Source records
- pubmed · retrieved 2026-09-25T12:28:14.353Z
- europe-pmc · retrieved 2026-09-25T12:28:14.363Z
- doaj · retrieved 2026-09-25T12:28:14.365Z